Kidney biopsy in patients with small kidneys: diagnostic yield and treatment modification in a retrospective cohort study Authors: Wen Wang, Xing Chen, Ruopei Wang, Lijing Yao, Lu Zhang Published: 2026 ABSTRACT AbstractBackgroundReduced renal size has traditionally been considered a relative contraindication to kidney biopsy because of the perception that advanced chronic damage provides limited diagnostic or therapeutic benefit. However, the actual clinical value of renal biopsy in patients with small kidneys remains insufficiently investigated.MethodsWe conducted a retrospective single-center study including patients with chronic kidney disease who underwent renal biopsy between June 2020 and December 2025. Patients with renal length ≤9 cm were defined as having small kidneys. Baseline clinical data, pathological diagnoses, treatment modifications following biopsy, and follow-up clinical outcomes were analyzed. Subgroup analyses were performed according to pathological categories.ResultsAmong 1,084 biopsied patients, 76 (7.0%) had small kidneys. Renal biopsy revealed heterogeneous etiologies, with IgA nephropathy (IgAN) accounting for 46.1% of cases. Treatment strategies were modified in 67.1% of patients after renal biopsy. During follow-up, biopsy-guided management was associated with reduced proteinuria and stable renal function.Conclusions In selected patients with small kidneys, renal biopsy was associated with high diagnostic yield and frequent treatment modifications.Keywords: Chronic kidney disease, small kidneys, renal biopsy, treatment modification, IgA nephropathy Introduction Chronic kidney disease (CKD) manifests a progressive decline in renal function, eventually progressing to end-stage renal disease (ESRD), which may lead to complications such as hypertension, anemia, bone and cardiovascular disease, and has become a major challenge in global public health [1–3]. Its prevalence exhibits an increasing trend globally [4]. During the progression of CKD, renal fibrosis is recognized as the core pathological pathway, which is characterized by the replacement of normal renal parenchyma by excessive extracellular matrix [5,6], leading to the destruction of organ structure and the progressive loss of function [5,7–11]. Reduced renal size is commonly interpreted as a morphological marker of advanced CKD and is traditionally associated with irreversible structural damage and limited therapeutic reversibility. However, small kidneys may also result from other conditions, such as congenital renal dysplasia or reflux nephropathy [12]. Consequently, patients with small kidneys have historically been considered less suitable candidates for kidney biopsy because the diagnostic yield was presumed to be low and unlikely to influence clinical management [13]. However, emerging evidence suggests that renal length alone does not reliably reflect the degree of active disease processes, and substantial pathological heterogeneity may exist even in patients with reduced renal dimensions [14]. Distinguishing potentially treatable etiologies from irreversible chronic lesions remains clinically important, particularly in patients presenting with persistent proteinuria, hematuria, or unexplained renal dysfunction. In such situations, pathology-guided diagnosis may significantly alter therapeutic decision-making, including the initiation of immunosuppressive therapy, genetic counseling, or targeted supportive interventions [15,16]. The definition of small kidneys varies across studies. Typically, the normal renal length in adults, ranging from 9.6 to 10.7 cm, is employed as a reference standard [17,18]. Small kidneys are typically identified by ultrasonography or computed tomography as kidneys with reduced renal length relative to expected normal values [19]. Because reduced renal size may result from diverse underlying diseases, imaging findings alone are often insufficient to establish the etiology. In such situations, kidney biopsy may provide definitive histopathological diagnosis and facilitate individualized treatment decisions [20–22]. Although small kidneys have traditionally been considered a relative contraindication to kidney biopsy because of concerns regarding limited diagnostic yield, advanced chronicity, and increased procedural risk, this recommendation has largely been based on expert opinion and general biopsy practice rather than dedicated evidence in patients with small kidneys [23,24]. Recent studies have demonstrated that ultrasound-guided percutaneous kidney biopsy can be performed safely in carefully selected patients with small kidneys, providing adequate tissue for histopathological evaluation while maintaining an acceptable complication rate [13,23,24]. These studies have also shown that biopsy frequently identifies potentially treatable kidney diseases despite reduced renal size, highlighting its diagnostic value in selected patients. However, the available evidence remains limited by small sample sizes and retrospective study designs. More importantly, evidence regarding how biopsy findings influence subsequent treatment modification and clinical outcomes remains limited, and disease-specific clinicopathological analyses, particularly in IgA nephropathy (IgAN), have rarely been reported. We therefore conducted a retrospective cohort study to evaluate the diagnostic spectrum, treatment modification rate, and clinical follow-up outcomes of patients with small kidneys who underwent renal biopsy at a tertiary referral center. We hypothesized that renal biopsy provides clinically meaningful decision-changing information even in patients traditionally considered suboptimal biopsy candidates. Materials and methods This study was approved by the Ethics Committee of The First Affiliated Hospital of Xiamen University (Approval No. 2024-177). The requirement for informed consent was waived by the Ethics Committee because this was a retrospective study using anonymized clinical data, and no identifiable personal information was involved, posing no additional risk to the participants. All patient data were collected in accordance with the approved protocol. The study was conducted in accordance with the principles of the Declaration of Helsinki. This study used a retrospective analysis method to include adult patients who underwent renal biopsy at The First Affiliated Hospital of Xiamen University from June 2020 to December 2025. Exclusion criteria were: (1) history of renal surgery; (2) severe renal artery stenosis or ischemic renal disease; (3) missing information in their medical files. Detailed clinical data were collected for each case, including basic patient information (gender, age, medical history), renal imaging findings, laboratory examination data (e.g., blood routine, liver and kidney function, urine routine), renal biopsy pathological information, and treatment adjustments. The primary outcome was treatment modification based on pathological findings. Secondary outcomes included changes in renal function (estimated glomerular filtration rate, eGFR), 24h urinary protein excretion (24h-UP), blood pressure control, and the development of ESRD related clinical manifestations. Small kidneys were defined a priori as a maximal renal length of ≤9.0 cm measured by renal ultrasonography or computed tomography. Renal length was recorded as the maximal bipolar length on standard longitudinal imaging planes. Because no universally accepted definition of small kidneys exists, a cutoff of ≤9.0 cm was adopted as an operational definition based on a previous study evaluating kidney biopsy in patients with reduced renal size [25,26]. This threshold was prespecified before data analysis. Although renal length correlates with body size, including height and weight, height or body surface area–adjusted thresholds have not been validated for guiding kidney biopsy decisions in routine clinical practice. Therefore, absolute renal length was used as a pragmatic and reproducible imaging-based criterion in this study. All renal biopsies included in this study were index biopsies. Renal biopsies were performed using a percutaneous ultrasound-guided approach. An automated spring-loaded biopsy device was used, with either a 16-gauge or 18-gauge needle selected at the operator’s discretion based on kidney size and individual patient characteristics. Typically, two to three passes were performed to obtain adequate cortical tissue. All procedures were conducted by experienced nephrologists with expertise in renal biopsy procedures, and patients were monitored according to standard institutional protocols. Statistical analysis Normality of continuous variables was assessed using the Shapiro-Wilk test. Data are presented as mean ± standard deviation or median (interquartile range), as appropriate, and categorical variables as number and percentage. Between-group comparisons were performed using the independent-samples t-test or Mann-Whitney U test for continuous variables and the chi-square test or Fisher’s exact test for categorical variables. Associations between renal length and baseline continuous variables, including age, body weight, height, and body mass index (BMI), were assessed using Spearman’s rank correlation analysis. Repeated measurements of 24h-UP and eGFR were analyzed using mixed-effects models for repeated measures (MMRM) under the assumption of missing at random, allowing inclusion of all available observations without imputation. Follow-up numbers gradually decreased over time due to loss to follow-up, which was not related to ESRD or death. Therefore, MMRM was considered appropriate for handling repeated measurements with incomplete follow-up. Proteinuria changes during follow-up were expressed according to the graphical presentation. Figure 1 presents proteinuria reduction from baseline, calculated as [(baseline 24h-UP − follow-up 24h-UP)/baseline 24h-UP] × 100%, whereas Figure 2 presents proteinuria change from baseline, calculated as [(follow-up 24h-UP − baseline 24h-UP)/baseline 24h-UP] × 100%. For Figure 2, negative values indicate a reduction in proteinuria compared with baseline, whereas positive values indicate an increase. Neither measure represents clinical remission. A two-sided P value < 0.05 was considered statistically significant. Longitudinal comparison of proteinuria reduction from baseline between the treatment modified and treatment unchanged groups after renal biopsy. Data are presented as the mean ± standard error of the mean (SEM) for the treatment modified group (n = 51) and the treatment unchanged group (n = 25). Intergroup comparisons at 3, 6, and 9 months were performed using independent-samples t-tests. The treatment modified group showed a significantly greater percent reduction in 24h-UP from baseline at 3, 6, and 9 months after biopsy (all P < 0.01). Longitudinal changes in urinary protein and renal function in patients with small kidneys by pathological subgroups. Estimated marginal means of urinary protein excretion and estimated glomerular filtration rate (eGFR) were derived from mixed-effects models for repeated measures (MMRM). Log-transformed urinary protein and eGFR were used as dependent variables, with time as a categorical factor. Values are presented as back-transformed estimates with 95% confidence intervals. (A) Overall cohort. Statistically significant reductions in urinary protein were observed at 3, 6, and 9 months compared with baseline. (B) IgAN subgroup. Statistically significant reductions in urinary protein were observed at 3, 6, and 9 months compared with baseline. (C) Non-IgAN subgroup. Statistically significant reductions in urinary protein were observed at 3, 6, and 9 months compared with baseline. (D–F) Longitudinal changes in proteinuria from baseline in the overall cohort (D), the IgAN subgroup (E), and the non-IgAN subgroup (F). (G–I) eGFR over time in the overall cohort (G), IgAN (H), and non-IgAN (I), with no significant changes at any time point. Asterisks indicate significant differences versus baseline (*P < 0.05, **P < 0.01, ***P < 0.001). Error bars represent 95% confidence intervals. Results Baseline and clinical characteristics of renal biopsy patients: a comparison of the small-kidney and overall cohorts We analyzed the data of 1,084 adult patients who were diagnosed with CKD and underwent renal biopsy in our hospital from June 2020 to December 2025. The median age was 40 (31–54) years. The median height was 164 (158–170) cm, the median weight was 63 (55–73) kg, and the renal length was 10.3 (9.7–10.9) cm. In the overall cohort (n = 1,084), renal length positively correlated with both height and body weight (Table 1), consistent with previous population-based imaging studies. Based on the prespecified cutoff derived from the literature, patients with a maximum renal length of ≤9.0 cm were classified as having small kidneys. In the present cohort, this threshold was below the median renal length [10.3 (9.7–10.9) cm], indicating that these patients represented a subgroup with unequivocally reduced renal size. Accordingly, the predefined cutoff of 9.0 cm was used for subsequent analyses evaluating the clinicopathological characteristics and clinical utility of renal biopsy in patients with small kidneys. According to the predefined threshold above, 76 patients with small kidneys (7.0%) comprised the final study cohort. Table 2 presents the baseline characteristics, including age, gender, height, weight, BMI, renal length, and indication for kidney biopsy. There were 29 males (38.2%) and 47 females (61.8%), with a median age of 50.5 (38–59.75) years. The average height was 160 ± 6.61 cm, the average weight was 57.2 ± 8.58 kg, the average BMI was 22.3 ± 2.76 kg/m2, and the median length of the kidney was 8.8 (8.53–8.98) cm. The most common indication for renal biopsy was impaired renal function (48.7%), defined as CKD of unknown etiology or unexplained decline in renal function rather than acute kidney injury, followed by nephritic syndrome (20, 26.3%). Table 3 summarizes the clinical parameters, including systolic blood pressure (SBP), diastolic blood pressure (DBP), hemoglobin (Hb) level, serum creatinine, blood urea nitrogen (BUN), urinary red blood cell (RBC) count, 24h-UP and eGFR. Before renal biopsy, the mean SBP and DBP were 146.3 ± 15.76 and 91.1 ± 17.08 mmHg, respectively. The median Hb was 122 (107.5–131) g/L, the median serum creatinine was 118 (80.75–183.3) μmol/L, the mean eGFR was 59.5 ± 28.6 mL/min/1.73 m2, the median urinary RBC count was 57.9 (24.73–122.9)/μL and the median 24h-UP was 789 (300–2056) mg/d. Table 1.Baseline characteristics of all patients and their association with renal length (n = 1,084).CharacteristicTotal cohort (n = 1,084)P value for association with renal lengthAge (years)40 (31–54)<0.0001Renal length (cm)10.3 (9.7–10.9)—Height (cm)164 (158–170)<0.0001Weight (kg)63 (55–73)<0.0001BMI (kg/m2)23.52 (21.3–26.3)<0.0001Associations between renal length and baseline characteristics were assessed using Spearman’s rank correlation analysis. Abbreviations: BMI, body mass index. Baseline characteristics of all patients and their association with renal length (n = 1,084). Associations between renal length and baseline characteristics were assessed using Spearman’s rank correlation analysis. Abbreviations: BMI, body mass index. Table 2.Comparison of baseline characteristics between the small kidneys and non-small kidneys subgroups.VariableSmall kidneys (n = 76)Non-small kidneys (n = 1,008)P valueAge (years)50.5 (38–59.75)40 (31–53)<0.0001Sex (female)47 (61.8%)490 (48.6%)/Height (cm)160 ± 6.61164.5 ± 8.17<0.0001Weight (kg)57.2 ± 8.5865.51 ± 12.9<0.0001BMI (kg/m2)22.3 ± 2.7624.08 ± 3.73<0.0001Type of hospital settinginpatient (100%)inpatient (100%)/Renal length (cm)8.8 (8.53–8.98)10.4 (9.8–11)<0.0001Indication for kidney biopsyImpaired renal function (37, 48.7%)Nephritic syndrome (20, 26.3%)Nephrotic syndrome (7, 9.2%)Proteinuria (7, 9.2%)Hematuria ± proteinuria (5, 6.6%)Impaired renal function (159, 15.8%)Nephritic syndrome (299, 29.7%)Nephrotic syndrome (270, 26.8%)Proteinuria (116, 11.5%)Hematuria ± proteinuria (48, 4.8%)Other (116, 11.5%)/Impaired renal function refers to chronic kidney disease of unknown etiology or with unexplained decline in renal function, rather than acute kidney injury. Other: includes 36 non-renal-specific diagnoses, systemic lupus erythematosus (18), edema (15), henoch-schönlein purpura (13), hypertension (12), diabetic nephropathy (10), type 2 diabetes (8), etc. Abbreviations: BMI, body mass index. Comparison of baseline characteristics between the small kidneys and non-small kidneys subgroups. Impaired renal function refers to chronic kidney disease of unknown etiology or with unexplained decline in renal function, rather than acute kidney injury. Other: includes 36 non-renal-specific diagnoses, systemic lupus erythematosus (18), edema (15), henoch-schönlein purpura (13), hypertension (12), diabetic nephropathy (10), type 2 diabetes (8), etc. Abbreviations: BMI, body mass index. Table 3.Comparison of clinical characteristics between the small kidneys and non-small kidneys subgroups.VariableSmall kidneys (n = 76)Non-small kidneys (n = 1,008)P valueSBP (mmHg)146.3 ± 15.76148.2 ± 17.420.259DBP (mmHg)91.1 ± 17.0890.23 ± 13.210.259Hb (g/L)122 (107.5–131)129 (114–144)0.0005Serum creatinine (μmol/L)118 (80.75–183.3)86 (63–123)<0.0001BUN (mmol/L)7.9 (5.43–11.2)5.66 (4.42–8.18)<0.0001Urinary RBC count (/μL)57.9 (24.73–122.9)86.1 (37.8–245.1)0.01724h-UP (mg/d)789 (300–2056)1733 (691–4166)<0.0001eGFR (mL/min/1.73 m2)59.5 ± 28.683.95 ± 33.82<0.0001CKD stageG1 (8, 10.5%)G2 (20, 26.3%)G3a (21, 27.6%)G3b (15, 19.7%)G4 (5, 6.6%)G5 (7, 9.2%)//Continuous variables are presented as mean ± SD or median (IQR), and categorical variables as number (%). Between-group comparisons were performed using the appropriate tests as described in Methods. A two-sided P value < 0.05 was considered statistically significant. Abbreviations: CKD, chronic kidney disease; SBP, systolic blood pressure; DBP, diastolic blood pressure; Hb, hemoglobin; BUN, blood urea nitrogen; RBC, red blood cell; 24h-UP, 24-h urinary protein excretion; eGFR, estimated glomerular filtration rate. Comparison of clinical characteristics between the small kidneys and non-small kidneys subgroups. Continuous variables are presented as mean ± SD or median (IQR), and categorical variables as number (%). Between-group comparisons were performed using the appropriate tests as described in Methods. A two-sided P value < 0.05 was considered statistically significant. Abbreviations: CKD, chronic kidney disease; SBP, systolic blood pressure; DBP, diastolic blood pressure; Hb, hemoglobin; BUN, blood urea nitrogen; RBC, red blood cell; 24h-UP, 24-h urinary protein excretion; eGFR, estimated glomerular filtration rate. Pathological diagnosis and treatment modification of 76 patients with small kidneys 76 patients with small kidneys underwent renal biopsy without serious adverse events (SAEs). All biopsy specimens were considered adequate for histopathological diagnosis, with a mean yield of 12 glomeruli per biopsy, allowing reliable pathological evaluation. IgAN accounted for the most common pathological diagnosis (35 cases, 46.1%), followed by diabetic nephropathy (DN) (6 cases, 7.9%) and thin basement membrane disease (TBMN) (4 cases, 5.3%). The remaining 31 patients were categorized as ‘other’ types, encompassing a diverse pattern of pathological diagnoses, such as allergic purpura nephritis (also named as IgA vasculitis), antineutrophil cytoplasmic antibody-associated vasculitis (AAV), Alport syndrome, and monoclonal gammopathy of renal significance (MGRS), among others. Besides glomerular diseases, this category also encompassed various forms of acute and chronic tubulointerstitial injury. Treatment modification was defined as any change in therapeutic strategy after renal biopsy based on pathological findings, including initiation, escalation, reduction, or discontinuation of immunosuppressive therapy, optimization of supportive therapy, or other pathology-guided management. Unchanged treatment was defined as no modification of the treatment regimen after biopsy. All treatment decisions were made according to Kidney Disease: Improving Global Outcomes (KDIGO) recommendations and disease-specific clinical practice. Overall, biopsy-guided treatment modification was observed in 51 patients (67.1%) (Table 4). The overall treatment modification rate was 80.0% in the IgAN subgroup and 56.1% in the non-IgAN subgroup (Fisher’s exact test, P = 0.031). Because treatment modification categories were not mutually exclusive, individual treatment modifications are presented descriptively. In the IgAN subgroup, immunosuppressive therapy was initiated or intensified in 28 patients (80.0%) after biopsy. In addition, 7 patients (20%) demonstrated predominantly chronic pathological changes; therefore, no modification of the preexisting treatment regimen was made after biopsy, and supportive therapy was continued. In the non-IgAN subgroup, immunosuppressive therapy was initiated or adjusted in 13 patients (31.7%), supportive therapy was further optimized in seven patients (17.1%), and genetic testing-guided management was initiated in five patients. Treatment modifications were analyzed by category and were not mutually exclusive. Therapeutic decisions were guided by the corresponding pathological diagnoses and are described according to pathological subgroup in the subsequent analyses. Table 4.Baseline treatment strategies and biopsy-guided treatment modifications in patients with IgAN and non-IgAN.VariableIgAN (n = 35)Non-IgAN (n = 41)PImmunosuppressive therapy before biopsy Receiving immunosuppressive therapy0 (0%)2 (4.9%)/Not receiving immunosuppressive therapy35 (100%)39 (95.1%)/Immunosuppressive therapy modification after biopsy Initiation of immunosuppressive therapy28 (80.0%)11 (26.8%)/Up-titration due to active inflammatory lesions0 (0%)1 (2.4%)/Down-titration or discontinuation due to chronic lesions0 (0%)1 (2.4%)/Supportive therapy maintained because of chronic pathological lesions7 (20.0%)28 (68.3%)/Supportive treatment modification after biopsy Initiation or intensification of ACEI/ARB12 (34.3%)5 (12.2%)/Initiation or up-titration of SGLT2 inhibitors2 (5.7%)1 (2.4%)/Further optimization of blood pressure management2 (5.7%)1 (2.4%)/Biopsy-guided treatment modification Treatment modified28 (80.0%)23 (56.1%)0.031Treatment unchanged7 (20.0%)18 (43.9%)Data are presented as n (%). Treatment modification categories were not mutually exclusive, and individual patients could receive more than one treatment modification. Therefore, the sum of individual treatment categories may exceed the number of patients with overall treatment modification. Overall treatment modification was compared between pathological subgroups using Fisher’s exact test. Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; SGLT2, sodium–glucose cotransporter 2. Baseline treatment strategies and biopsy-guided treatment modifications in patients with IgAN and non-IgAN. Data are presented as n (%). Treatment modification categories were not mutually exclusive, and individual patients could receive more than one treatment modification. Therefore, the sum of individual treatment categories may exceed the number of patients with overall treatment modification. Overall treatment modification was compared between pathological subgroups using Fisher’s exact test. Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; SGLT2, sodium–glucose cotransporter 2. Patients were then divided into two groups according to whether the treatment regimen was modified after renal biopsy (Figure 1). Subsequently, 24h-UP over time was statistically analyzed. At baseline, the 24h-UP reduction rate was comparable between the treatment modified and treatment unchanged groups. At 3, 6, and 9 months, patients with small kidneys whose treatment was modified based on renal biopsy pathology exhibited significantly higher 24h-UP reduction rates than those without treatment modification, with statistically significant differences observed at all post-baseline time points (all P < 0.01). Pathological findings and biopsy-guided management according to pathological diagnosis of 76 patients with small kidneys In the IgAN (n = 35, 46.1%) and non-IgAN (n = 41, 53.9%) subgroups, the clinical baseline characteristics are shown in Table 5. These subgroup analyses were performed to describe pathological features and biopsy-guided management within each diagnostic category rather than to compare disease prognosis or treatment response between groups. Table 5.Comparison of baseline characteristics between patients with IgAN and non-IgAN. IgAN (n = 35)non-IgAN (n = 41)PAge (years)43.49 ± 11.358 (43.5–65)<0.001Height (cm)160.8 ± 6.55159.3 ± 6.650.31Weight (kg)58.49 ± 8.0956.09 ± 8.920.23Renal length (cm)8.7 (8.5–8.9)8.8 (8.6–9)0.07SBP (mmHg)145.5 ± 16.15147.2 ± 15.90.305DBP (mmHg)96 ± 9.8285.86 ± 21.620.028Hb (g/L)123.8 ± 17.25118 (98–129.5)0.057Serum creatinine (μmol/L)127 (89–177)109 (73.5–198)0.236BUN (mmol/L)8.1 (5.94–9.65)6.86 (4.85–11.65)0.382Blood glucose (mmol/L)4.52 (4.18–4.76)5.04 (4.49–5.46)0.0001Total cholesterol (mmol/L)5.07 ± 1.155.36 (4.13–6.45)0.068Urinary RBC count (/μL)50.9 (28.6–112.3)83.8 (19.3–226.7)0.35224h-UP (mg/d)769.5 (296.5–1367)789 (272–3441)0.47eGFR (mL/min/1.73 m2)58.99 ± 23.8560.46 ± 33.470.86Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure; Hb, hemoglobin; BUN, blood urea nitrogen; RBC, red blood cell; 24h-UP, 24-h urinary protein excretion; eGFR, estimated glomerular filtration rate. Comparison of baseline characteristics between patients with IgAN and non-IgAN. Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure; Hb, hemoglobin; BUN, blood urea nitrogen; RBC, red blood cell; 24h-UP, 24-h urinary protein excretion; eGFR, estimated glomerular filtration rate. In the IgAN subgroup (n = 35), according to the Lee’s grades, there were 4 cases of grade II, 14 cases of grade III, 12 cases of grade IV, and 5 cases of grade V (Figure 3(A)). According to the Oxford classification, MEST-C scores were as follows: mesangial proliferation (M), M1 in 32 cases (91.4%); endocapillary hypercellularity (E), E1 in 4 cases (11.4%); segmental glomerulosclerosis (S), S1 in 24 cases (68.6%); tubular atrophy/interstitial fibrosis (T), T1 in 8 cases (22.9%) and T2 in 6 cases (17.1%); cellular or fibrocellular crescents (C), C1 in 10 cases (28.6%) and no C2 cases (0%) (Figure 3(B)). Despite reduced renal length, many IgAN patients showed only limited to moderate chronic lesions, instead of uniformly advanced scarring. In the 35 cases of IgAN, immunosuppressive therapy was initiated in 28 cases (80%) after pathological diagnosis. Among these 28 patients, 92.9% had M1, 7.1% had E1, 67.9% had S1, 39.3% had T1 or T2, and 32.1% had C1. Only 7 cases (20%) remained on supportive treatment. Comparative pathological spectra of the IgAN and non-IgAN subgroups. (A) Distribution of Lee’s grades in the IgAN subgroup (n = 35): Cases were graded as II (n = 4), III (n = 14), IV (n = 12), and V (n = 5). (B) Prevalence of Oxford MEST-C classification in the IgAN subgroup (n = 35): Frequencies are shown for M1 (91.4%), E1 in 4 cases (11.4%), S1 (68.6%), T1 + T2 (40.0%), and C1 (28.6%). (C) Distribution of disease categories in the non-IgAN subgroup, including glomerular-dominant diseases (n = 27), tubulointerstitial-dominant diseases (n = 9), and genetic kidney diseases (n = 5). Glomerular-dominant diseases included minimal change disease, membranous nephropathy, and focal segmental glomerulosclerosis-like lesions. Oxford MEST-C classification: M, mesangial hypercellularity; E, endocapillary hypercellularity; S, segmental glomerulosclerosis or adhesion; T, tubular atrophy/interstitial fibrosis; C, cellular or fibrocellular crescents. In the non-IgAN subgroup (n = 41), glomerular-dominant diseases accounted for 27 cases (65.9%), including minimal change disease (MCD, 4, 9.8%), membranous nephropathy (MN, 3, 7.3%), focal segmental glomerulosclerosis (FSGS)-like lesions (2, 4.9%), immune complex–mediated or proliferative glomerulonephritis (4, 9.8%), diabetic or hypertension-related glomerular lesions (14, 34.1%), AAV (1, 2.4%), and drug-related or rare immune lesions (3, 7.3%). Tubulointerstitial-dominant diseases accounted for 9 cases (22.0%), most of which showed chronic lesions with superimposed acute injury. Genetic kidney diseases totaled 5 (12.2%), including TBMN (4, 9.8%) and suspected Alport syndrome (1, 2.4%) (Figure 3(C)). Variable degrees of chronic pathological changes were observed across these entities, including glomerulosclerosis and interstitial fibrosis/tubular atrophy. Overall, 23 patients (56.1%) had treatment adjustments based on biopsy results, mainly targeting reversible or immunologically active conditions (MCD, MN, FSGS-like lesions, TBMN, etc.), with interventions primarily involving initiation or escalation of corticosteroids and/or immunosuppressants. Genetic kidney disease patients received supportive care and genetic counseling, whereas DN, hypertension-related glomerular lesions, and tubulointerstitial diseases were managed with standard baseline therapy. Clinical follow-up: longitudinal changes in proteinuria and renal function in patients with small kidneys stratified by pathological subgroups In our ‘small kidney cohort’ of 76 cases, 24h-UP was significantly decreased compared with the baseline at 3, 6, and 9 months of follow-up (Figure 2(A)). The reductions were 32.6%, 19.6%, and 33.6% (P < 0.001), respectively (Figure 2(D)). In the IgAN subgroup, 24h-UP showed significant decreases compared with baseline at 3, 6, and 9 months (Figure 2(B)), with reductions of 46.4%, 46.7%, and 64.2% (P < 0.01) (Figure 2(E)). In the non-IgAN subgroup, 24h-UP was significantly reduced at all follow-up timepoints compared with baseline (Figure 2(C)). 24h-UP reductions were 15.2% at 3 months, 45.7% at 6 months, and 40.0% at 9 months (P < 0.05) (Figure 2(F)). As for renal function, estimated glomerular filtration rate (eGFR) remained relatively stable during the 9-month follow-up period. No significant differences in eGFR were observed at 3, 6, or 9 months compared with baseline in the overall cohort, the IgAN subgroup, or the non-IgAN subgroup (Figure 2(G–I)). Safety outcomes Among patients undergoing biopsy of small kidneys, the observed bleeding complications were mild to moderate and consisted primarily of small perinephric hematomas (15 cases, 19.7%), and mild hematuria (10 cases, 13.2%). No perinephric hematoma exceeded 3 cm in diameter, and no patient required blood transfusion or interventional embolization, nor did any case result in prolonged hospitalization. All bleeding events resolved spontaneously under conservative management and no other complications or SAEs were observed during the study period. Discussion In this retrospective cohort study, we found that renal biopsy was associated with substantial clinical utility in patients with small kidneys, a population traditionally considered less suitable for invasive diagnostic evaluation. Our results showed that renal biopsy in patients with small kidneys was associated with the identification of a broad spectrum of underlying etiologies and with treatment modification in nearly two-thirds of cases. These observations call into question the conventional assumption that small kidneys invariably reflect irreversible chronic damage with limited diagnostic or therapeutic relevance. As pathological examination of renal tissue remains the gold standard for the diagnosis of kidney disease [13,15,27,28], its role in translating nonspecific clinical manifestations into precise histopathological diagnoses may be particularly relevant in this challenging population. Reduced renal size is often considered a manifestation of CKD progression, and concerns regarding limited diagnostic yield may influence decisions regarding kidney biopsy. Previous studies have suggested that kidney biopsy can still provide clinically relevant pathological information in selected patients with small kidneys, with acceptable procedural safety. Consistent with previous reports, our study showed that kidney biopsy in patients with reduced renal length provided adequate tissue for pathological evaluation without severe biopsy-related adverse events. However, beyond procedural feasibility, our findings further showed that biopsy results contributed to subsequent treatment adjustments. Despite reduced renal size, pathological findings in our cohort were heterogeneous, and IgAN remained the most common pathological diagnosis, consistent with regional disease patterns reported in southern Fujian [29–33]. These findings suggest that renal size alone may not fully reflect the underlying pathological status. In light of the observed pathological heterogeneity among patients with small kidneys, particularly the presence of limited or moderate chronic lesions in a substantial proportion of IgAN cases, reliance on renal size alone may be insufficient for clinical decision-making. This underscores the potential value of histological evaluation in selected patients with reduced renal length. Within this context, the clinical value of renal biopsy in patients with small kidneys is further underscored in those with IgAN. A number of multicenter studies with large sample sizes and reviews have shown that the pathological indicators in the Oxford MEST-C scoring system are independently associated with the progression of renal function and the risk of ESRD in patients with IgAN. T was the most stable and strongest risk factor, followed by S, M, and C [34–39]. Consistent with these observations, greater histological severity identified by biopsy was associated with a higher likelihood of treatment modification in our cohort, suggesting that pathological findings were closely linked to therapeutic decision-making. This suggests that in the absence of pathological guidance, clinicians may be inclined to adopt a conservative observation strategy for patients with IgAN presenting with isolated hematuria and/or mild proteinuria; the pathological activity revealed by renal biopsy prompts clinicians to initiate immunosuppressive therapy more actively to inhibit inflammation and delay disease progression. In this setting, renal biopsy may shift management from nonspecific observation to more targeted, individualized treatment. Although renal biopsy was associated with potential clinical utility in patients with small kidneys, several limitations should be acknowledged. First, this was a single-center retrospective observational study, and referral patterns and sample composition may have been influenced by regional anthropometric and ethnic characteristics, limiting generalizability. Second, the study could not reliably distinguish constitutionally small kidneys from renal shrinkage due to CKD progression. Because information on disease duration, baseline renal function at disease onset, and prior kidney size was not consistently available, predefined restrictions based on these factors could not be applied. This reflects real-world practice, in which biopsy decisions are often made without longitudinal imaging or early disease documentation. Importantly, inclusion of patients with potentially long-standing CKD would be expected to bias against, rather than exaggerate, the observed diagnostic yield and treatment-modifying associations. Third, the retrospective design limited the availability of appropriate comparison groups. We were unable to include a contemporaneous group of patients with small kidneys who did not undergo kidney biopsy; therefore, the observed changes following biopsy-guided management cannot be interpreted as causal effects of biopsy alone, and improvements in proteinuria may have been partially influenced by supportive therapy optimization or other unmeasured factors. In addition, direct comparison with patients with normal renal size was not performed. Although previous studies have evaluated differences in biopsy findings and outcomes according to kidney size [13,40–43], the present study was specifically designed to characterize pathological heterogeneity and biopsy-guided management within the small kidney population. Therefore, whether the diagnostic spectrum, treatment modifications, and clinical outcomes observed in patients with small kidneys differ from those in patients with normal-sized kidneys remains to be further investigated. Finally, incomplete and irregular follow-up precluded robust conclusions regarding long-term renal survival, ESRD, or mortality. Accordingly, observations related to disease progression should be interpreted as hypothesis-generating. As a retrospective observational study, residual confounding by indication cannot be fully excluded, particularly regarding associations between biopsy-guided immunosuppressive therapy and short-term proteinuria changes. Conclusion In this retrospective cohort, renal biopsy in selected patients with small kidneys yielded clinically relevant diagnostic information and frequently altered subsequent management. Biopsy-guided treatment was associated with lower proteinuria and stable eGFR during short-term follow-up. These findings suggest that reduced renal length alone should not automatically preclude biopsy when clinically actionable disease remains a consideration. Further prospective studies are required to define the effect of this approach on long-term kidney outcomes. Funding Statement This work was supported by the Fujian Provincial Health Technology Project under Grant No. 2025J011436; and the Xiamen Municipal Health Guidance Project under Grant No. 3502Z20254ZD1017. Disclosure statement The authors report there are no competing interests to declare. Social media hook Small kidneys should not automatically preclude kidney biopsy in selected patients. Data availability statement The data that support the findings of this study are available from the corresponding author upon reasonable request. The data are not publicly available due to ethical and privacy restrictions, as they contain clinical information that could compromise the privacy of research participants. References Associated Data Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request. The data are not publicly available due to ethical and privacy restrictions, as they contain clinical information that could compromise the privacy of research participants.